Phase 2 Clinical Trial of KH617

NCT ID: NCT07138001

Last Updated: 2025-08-22

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-31
• Study Completion Date: 2030-12-31

Brief Summary

To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma

Conditions

Recurrent Glioblastoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

KH617+TMZ

KH617： 33mg/kg intravenous infusion, every 4 weeks as one cycle.

TMZ（5/28）：150~200mg/m2/d, oral, every 4 weeks as one cycle.

Group Type: EXPERIMENTAL

KH617+TMZ

Intervention Type: COMBINATION_PRODUCT

use KH617 and TMZ(5/28) as Combination Product.

KH617

KH617： 33mg/kg intravenous infusion, every 4 weeks as one cycle.

Group Type: EXPERIMENTAL

KH617

Intervention Type: DRUG

Single Clinical trial investigational drug

TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

TMZ（7/7）： 100-150 mg/m2/d，oral, alternating weekly,every 4 weeks as one cycle.

Platinum (cisplatin or carboplatin)+VP-16： Cisplatin for injection 80-100mg/m2, divided into 3 days, the dose depends on tolerability, every 4 weeks as one cycle; carboplatin injection 75-100mg/m2/d, continuously administered for 3 days, the dose depends on tolerability, every 4 weeks as one cycle; etoposide injection 100mg/m2/d, continuously administered for 3 days, every 4 weeks as one cycle.

Group Type: ACTIVE_COMPARATOR

TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

Intervention Type: DRUG

Comparator product, Two treatment options for physicians and subjects to choose from:

1. use TMZ(7/7)

2. Use Platinum (cisplatin or carboplatin)+VP-16

Interventions

KH617+TMZ

use KH617 and TMZ(5/28) as Combination Product.

Intervention Type: COMBINATION_PRODUCT

KH617

Single Clinical trial investigational drug

Intervention Type: DRUG

TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

Comparator product, Two treatment options for physicians and subjects to choose from:

1. use TMZ(7/7)

2. Use Platinum (cisplatin or carboplatin)+VP-16

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female,age≥18 years old.

2. Life expectancy of at least 3 months.

3. Glioblastoma confirmed by histopathology.

4. Glioblastoma that recurred for the first time after failure of standard treatment.

5. Patient has at least one measurable lesion by iRANO.

6. MGMT promoter is unmethylated.

7. KPS≥ 60.

8. Adequate organ and bone marrow reserve function.

Exclusion Criteria

1. Pregnant or breastfeeding women, or women or men who are planning to have children.

2. Patients who have received the following treatments before enrollment should be excluded:

1. Patients who have received surgery, chemotherapy, targeted and immune drug therapy, iodine internal radiation, or radiotherapy within 4 weeks or 5 half-lives (whichever is shorter) before enrollment or who plan to receive radiotherapy during the trial.

2. Patients who had undergone intracranial lesion biopsy within 7 days before enrollment.

3. Received other clinical research drugs or treatments within 4 weeks before enrollment.

4. Received treatment with traditional Chinese medicine or Chinese patent medicine with anti-tumor effects within 1 week before enrollment.

3. History of central nervous system hemorrhage/infarction, such as ischemic/hemorrhagic stroke, within 6 months before enrollment.

4. Known history of unstable angina, myocardial infarction, or congestive heart failure within the past 6 months or clinically significant arrhythmia requiring antiarrhythmic therapy.

5. Poorly controlled high blood pressure or diabetes.

6. Uncontrolled pleural effusion, pericardial effusion, or ascites.

7. Patients at risk for active autoimmune disease or those with a history of autoimmune disease that may involve the central nervous system.

8. Pulmonary disease defined as grade ≥3 according to NCI-CTCAE v5.0.

9. Significant active bleeding within 6 months before the first dose.

10. Newly diagnosed thromboembolic events requiring treatment within 6 months before the first dose.

11. Other malignant tumors diagnosed within 5 years before the first dose.

12. Known allergy to any component of KH617.

13. Positive human immunodeficiency virus (HIV) antibodies, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and the presence of untreated or currently treated tuberculosis in the patient.

14. Patients who have received allogeneic cell or solid organ transplantation.

15. Active infection requiring systemic therapy.

16. Known history of psychotropic substance abuse, alcoholism, or drug abuse.

17. Other circumstances that the researcher deems unsuitable for participation in this clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sichuan Honghe Biotechnology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wenbin Li

Role: PRINCIPAL_INVESTIGATOR

Beijing Titan Hospital,Capital Medical University

Central Contacts

Manxi Zhao

Role: CONTACT

zhaomanqian@cnkh.com

86 15882459305

Jiaojiao Liang

Role: CONTACT

027056@cnkh.com

86 18180980577

Other Identifiers

KH617-30201

Identifier Type: -

Identifier Source: org_study_id